ObsEva is a biopharmaceutical company based in Geneva, Switzerland. Actively observing the price movement of the company in the last trading, the stock closed the session at $1.5300. And, today, in the pre-market trading, it is getting higher by reaching 19% to $1.8300. Investors cheered the announcement, as evidenced by today’s rally, and many are hoping that the news will fuel a more significant rally in ObsEva’s share price. According to the latest news, the Company is pleased to announce that from February 1 Katja Buhrer has been assigned Chief Strategy Officer and a member of the Company’s executive committee.
Ms. Buhrer will be in charge of the group’s strategy, as well as investor and media relations, according to a press release. The new manager previously worked for the veterinary laboratory Kindred Biosciences and MBS Value Partners. Separately, ObsEva has decided to expand its capital. The Company announced on Friday evening that the board of directors is planning the issuance of 23.4 million additional shares at a unit price of 1/13 franc per share. With this operation, the total number of shares rises to 108.62 million.